Sotagliflozin Versus Empagliflozin Added to Metformin for Glycemic Control in Type 2 Diabetes
Comparison of the Effect of Metformin-Sotagliflozin Versus Metformin-Empagliflozin Combination Therapy on Glycemic Control Measured by HbA1c in Patients With Type 2 Diabetes Mellitus
The goal of this randomized controlled trial is to compare two medicines added to metformin for blood sugar control in adults with type 2 diabetes whose HbA1c remains between 7.0% and 10.0% despite a stable dose of metformin. The main question it aims to answer is: Does adding sotagliflozin (a dual SGLT1/SGLT2 inhibitor) lower HbA1c more than adding empagliflozin (a selective SGLT2 inhibitor) after 24 weeks? Participants will continue their usual metformin dose and will be randomly assigned to take either sotagliflozin 200 mg or empagliflozin 10 mg once daily for 24 weeks. They will be reviewed at 4, 12 and 24 weeks for adherence, side effects and adverse events, and HbA1c will be measured at baseline and at 24 weeks.
調査の概要
状態
詳細な説明
Pakistan has one of the highest adult diabetes prevalences in the world, and many patients fail to reach HbA1c targets on metformin monotherapy and require a second agent. SGLT2 inhibitors such as empagliflozin are established second-line agents. Sotagliflozin additionally inhibits intestinal SGLT1, blunting post-prandial glucose absorption and enhancing incretin release, which may provide additional glucose lowering. No head-to-head randomized comparison of these two combinations has been performed in Pakistan.
This is a single-centre, open-label, parallel-group randomized controlled trial with blinded outcome assessment, conducted at the Department of Medicine and Diabetic Clinic/Medicine OPD, Allied Hospital-I, Faisalabad Medical University. 140 patients (70 per group) will be enrolled by consecutive sampling and randomized 1:1. Sample size was calculated for 95% confidence, 80% power, SD of HbA1c change 1%, and a minimal clinically important difference of 0.5%, inflated by 10% for loss to follow-up. HbA1c will be measured by a standardized laboratory method at baseline and 24 weeks, with laboratory staff blinded to group allocation. Data will be analysed in SPSS; mean change in HbA1c will be compared using the independent-samples t-test (p ≤ 0.05 significant), with stratification for age, gender, BMI, duration of diabetes and baseline HbA1c.
研究の種類
入学 (推定)
段階
- フェーズ 4
連絡先と場所
研究連絡先
- 名前:Sheraz Ali
- 電話番号:+923330360744
- メール:sheraz.mirza10@gmail.com
研究場所
-
-
Punjab Province
-
Faisalabad、Punjab Province、パキスタン、38000
- Allied Hospital, Faisalabad Medical University
-
コンタクト:
- Sheraz Ali
- 電話番号:03330360744
- メール:sheraz.mirza10@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age 30 to 65 years, male or female
- Diagnosed type 2 diabetes mellitus (ADA criteria)
- Inadequately controlled on metformin: stable dose ≥1500 mg/day (or maximum tolerated dose) for at least 8 weeks, with HbA1c ≥7.0% and ≤10.0% at screening
- Willing to provide written informed consent and attend scheduled follow-up
Exclusion Criteria:
- Type 1 diabetes mellitus or secondary diabetes
- Use of any SGLT inhibitor, GLP-1 receptor agonist, DPP-4 inhibitor or sulfonylurea within the previous 8 weeks
- eGFR <45 mL/min/1.73 m², or significant hepatic impairment
- Pregnancy, lactation, or women of childbearing potential not using contraception
- Haemoglobinopathies
- Known hypersensitivity to any study drug, or any condition making the patient unsuitable for the trial
- Recurrent genital/urinary tract infections or history of Fournier's gangrene
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Metformin + Sotagliflozin (Group A)
Existing stable dose of metformin plus sotagliflozin 200 mg orally once daily for 24 weeks. |
200 mg tablet orally once daily for 24 weeks continued at the participant's existing stable dose (≥1500 mg/day or maximum tolerated) |
|
アクティブコンパレータ:Metformin + Empagliflozin (Group B)
Existing stable dose of metformin plus empagliflozin 10 mg orally once daily for 24 weeks. |
continued at the participant's existing stable dose (≥1500 mg/day or maximum tolerated) 10 mg tablet orally once daily for 24 weeks |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in HbA1c From Baseline to Week 24
時間枠:Baseline and 24 weeks
|
Glycated haemoglobin (%) measured by a standardized laboratory method. Change calculated as baseline HbA1c minus week-24 HbA1c for each participant; a between-group difference ≥0.5% is considered clinically meaningful. |
Baseline and 24 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Adverse Events
時間枠:Up to 24 weeks (assessed at weeks 4, 12 and 24)
|
Adverse events including genital/urinary tract infections, hypoglycaemia and gastrointestinal symptoms, recorded at follow-up visits. |
Up to 24 weeks (assessed at weeks 4, 12 and 24)
|
協力者と研究者
捜査官
- 主任研究者:Sheraz Ali、Faisalabad Medical University
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 48.ERC/FMU/2025-26/434
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data will not be shared; aggregate results will be published in a peer-reviewed journal.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。